MX2022012471A - Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. - Google Patents

Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.

Info

Publication number
MX2022012471A
MX2022012471A MX2022012471A MX2022012471A MX2022012471A MX 2022012471 A MX2022012471 A MX 2022012471A MX 2022012471 A MX2022012471 A MX 2022012471A MX 2022012471 A MX2022012471 A MX 2022012471A MX 2022012471 A MX2022012471 A MX 2022012471A
Authority
MX
Mexico
Prior art keywords
inhibitors
menin
combinations
methods
cyp3a4
Prior art date
Application number
MX2022012471A
Other languages
English (en)
Inventor
Peter Ordentlich
Steven A Smith
Gerard M Mcgeehan
Galit Rosen
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of MX2022012471A publication Critical patent/MX2022012471A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención está dirigida a combinaciones de inhibidores de menina con uno o más inhibidores de CYP3A4, composiciones farmacéuticas de los mismos y métodos para tratar el cáncer y otras enfermedades mediadas por la interacción menina-MLL.
MX2022012471A 2020-04-07 2021-04-07 Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. MX2022012471A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063006574P 2020-04-07 2020-04-07
PCT/US2021/026141 WO2021207335A1 (en) 2020-04-07 2021-04-07 Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022012471A true MX2022012471A (es) 2022-11-30

Family

ID=78023861

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012471A MX2022012471A (es) 2020-04-07 2021-04-07 Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.

Country Status (10)

Country Link
US (1) US20230165858A1 (es)
EP (1) EP4132932A4 (es)
JP (1) JP2023522166A (es)
KR (1) KR20230007359A (es)
CN (1) CN115698013A (es)
AU (1) AU2021252552A1 (es)
CA (1) CA3178691A1 (es)
IL (1) IL297039A (es)
MX (1) MX2022012471A (es)
WO (1) WO2021207335A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240047338A (ko) 2021-05-14 2024-04-12 신닥스 파마슈티컬스, 인크. 메닌-mll 상호작용의 억제제
WO2023150635A1 (en) * 2022-02-04 2023-08-10 Kura Oncology, Inc. Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors
WO2023220098A1 (en) * 2022-05-09 2023-11-16 Syndax Pharmaceuticals, Inc. Menin-mll inhibitors for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466159B2 (en) * 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2956962A1 (en) * 2014-08-13 2016-02-18 Epizyme, Inc. Combination therapy for treating cancer
US10752639B2 (en) * 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
CN109562113A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
ES2831084T3 (es) * 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
WO2018175746A1 (en) * 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
JP7060694B2 (ja) * 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物

Also Published As

Publication number Publication date
CN115698013A (zh) 2023-02-03
WO2021207335A1 (en) 2021-10-14
AU2021252552A1 (en) 2022-10-27
US20230165858A1 (en) 2023-06-01
JP2023522166A (ja) 2023-05-29
IL297039A (en) 2022-12-01
KR20230007359A (ko) 2023-01-12
EP4132932A4 (en) 2024-04-17
EP4132932A1 (en) 2023-02-15
CA3178691A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
CR20220169A (es) Heterociclos bicíclicos como inhibidores de fgfr
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2022012471A (es) Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
WO2018136264A9 (en) Pyridine compounds as allosteric shp2 inhibitors
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
EA202091709A1 (ru) Ингибиторы днк-пк
EA201791866A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
CR20220207A (es) Compuestos terapéuticos y métodos de uso
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
EA202091708A1 (ru) Ингибиторы днк-пк
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MX2022001019A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
NZ747313A (en) Imidazolone compounds as human neutrophil elastase inhibitors